<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Chandrajit P Raut, MD, MSc, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Maki, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract are divided into two groups. The most common are neoplasms that are collectively referred to as gastrointestinal stromal tumors (GISTs). They are most often located in the stomach and proximal small intestine, but can occur in any portion of the alimentary tract and occasionally in the omentum, mesentery, and peritoneum [<a href="#rid1">1-5</a>].</p><p>A far less common group of mesenchymal GI tract neoplasms is comprised of a spectrum of tumors that are identical to those that might arise in the soft tissues throughout the rest of the body. These include lipomas, liposarcomas, leiomyomas, leiomyosarcomas, desmoid tumors, schwannomas, and peripheral nerve sheath tumors [<a href="#rid6">6</a>].</p><p>Local treatment options for GIST, leiomyomas, and leiomyosarcomas of the GI tract will be discussed here. The clinical presentation, diagnosis, and prognosis of GISTs, and the use of tyrosine kinase inhibitors (TKIs), both in the adjuvant and neoadjuvant setting, and for patients with metastatic GIST, are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">GENERAL SURGICAL PRINCIPLES</span><span class="headingEndMark"> — </span>The management of GISTs, leiomyomas, and leiomyosarcomas involving the gastrointestinal (GI) tract depends upon the confidence in the preoperative diagnosis, tumor location and size, extent of spread, and clinical presentation (eg, whether there is evidence of tumor obstruction, perforation, or uncontrolled hemorrhage). (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Clinical presentation'</a>.)</p><p>Some general surgical principles apply to these tumors regardless of location:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative biopsy</strong> – In most patients, a preoperative biopsy is obtained to distinguish a suspected GIST, leiomyoma, or leiomyosarcoma from other GI tumors, since the diagnosis impacts the extent of surgical margins and need for lymphadenectomy. A biopsy is preferred to confirm the diagnosis, especially for patients with large, locally advanced lesions suspected to be GIST who have metastatic disease or are eligible for neoadjuvant therapy  (<a class="graphic graphic_algorithm graphicRef139727" href="/d/graphic/139727.html" rel="external">algorithm 1</a>). However, a biopsy may not be necessary in patients if a mesenchymal GI tumor is strongly suspected, the tumor is resectable, and there is no safe approach for a biopsy. Available preoperative biopsy techniques for GIST are discussed separately. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Indications for preoperative biopsy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical resection for GIST ≥2 cm</strong> – All GISTs ≥2 cm in size should be resected. However, there is no consensus on the management of smaller GISTs ; guidelines from the National Comprehensive Cancer Network (NCCN) [<a href="#rid7">7</a>], European Society for Medical Oncology (ESMO) [<a href="#rid8">8</a>], and the Canadian advisory Committee on GIST [<a href="#rid9">9</a>] differ.</p><p></p><p class="bulletIndent1">The natural history of GISTs &lt;2 cm, including their growth rate and metastatic potential, remains unknown. Although these small GISTs may be followed endoscopically until they grow or become symptomatic, the optimal frequency of follow-up and specific risks of this strategy is uncertain. Successful endoscopic resection is reported, but it remains controversial because of the risk of incomplete resection, tumor spillage, and perforation [<a href="#rid10">10</a>]. Because GISTs are submucosal, standard techniques of endoscopic mucosal resection do not necessarily extend deep enough into the submucosal tissue to guarantee removal of all the deep tissue.</p><p></p><p class="bulletIndent1">An algorithmic approach to management of gastric GISTs based upon size and EUS appearance has been proposed  (<a class="graphic graphic_algorithm graphicRef139723" href="/d/graphic/139723.html" rel="external">algorithm 2</a>) [<a href="#rid11">11</a>]. This approach has been adopted by the NCCN [<a href="#rid7">7</a>] for gastric GISTs but not those at other sites in the GI tract. When endoscopic assessment is not possible, excision is the standard approach. (See <a class="local">'GIST and leiomyoma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neoadjuvant therapy for GIST </strong>– Surgery is the treatment of choice for potentially resectable tumors. However, initial neoadjuvant therapy  (<a class="graphic graphic_algorithm graphicRef139727" href="/d/graphic/139727.html" rel="external">algorithm 1</a>) may be preferred for some patients with GIST to facilitate resection and/or reduce surgical morbidity. Neoadjuvant therapy may allow patients to switch from an open to a minimally invasive (ie, laparoscopic or robotic) surgical approach, avoid complex multivisceral resection, or preserve the affected organ in those with disease involving the esophagus, esophagogastric junction, duodenum, or rectum. The approach to neoadjuvant therapy for GIST are discussed separately. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Neoadjuvant therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical approach</strong> - The goal of surgery is macroscopically complete resection with an intact capsule, if possible. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Segmental resection of the stomach or intestine should be performed with the goal of achieving negative resection margins. Wider resection of uninvolved tissue is of no additional benefit. However, peritumoral as opposed to segmental resection should be avoided, as there is a higher risk of local recurrence, particularly with leiomyosarcoma [<a href="#rid12">12</a>]. Routine lymphadenectomy is unnecessary because nodal metastases are rare [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent2">Although they may appear ominous on CT, GISTs often project extraluminally from the stomach or small intestine and displace rather than invade adjacent organs. They can often be lifted away from surrounding structures, although in some cases, en bloc resection is necessary because of dense adhesions.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At laparotomy, the abdomen should be thoroughly explored, with particular attention to the peritoneal surfaces and liver to exclude metastatic spread. The tumor should be handled carefully to avoid rupture, which markedly increases the risk of a disease recurrence. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Estimation of recurrence risk'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The necessity of achieving negative microscopic margins is uncertain with large (&gt;10 cm) GISTs. The management of a positive margin according to the final pathology report is not well defined and depends on whether the surgeon believes the finding accurately reflects the surgical procedure that was undertaken [<a href="#rid10">10,14</a>]. Positive microscopic margins (R1 resection) have not been associated with higher rates of recurrence compared with margin negative resections, with or without the use of adjuvant <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>. The risks and benefits of reexcision versus initiation of adjuvant therapy must be carefully evaluated [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjuvant therapy for GIST</strong> - Patients who undergo complete resection of localized GIST should be evaluated for adjuvant therapy based on the risk of disease recurrence  (<a class="graphic graphic_algorithm graphicRef139777" href="/d/graphic/139777.html" rel="external">algorithm 3</a>). The approach to adjuvant therapy for resected GIST is discussed separately. . (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Adjuvant therapy'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">STAGING AND PROGNOSIS</span></p><p class="headingAnchor" id="H346453822"><span class="h2">GIST</span><span class="headingEndMark"> — </span>The staging and prognosis of patients with a confirmed diagnosis of GIST is discussed separately. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Staging system'</a> and  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Risk stratification and prognosis'</a>.)</p><p class="headingAnchor" id="H3952807881"><span class="h2">Leiomyosarcoma</span><span class="headingEndMark"> — </span>The current staging system for soft tissue sarcomas (eighth edition, 2017) uses a specific tumor, node, metastasis (TNM) classification system for soft tissue sarcomas of the abdominal and thoracic viscera for leiomyosarcomas arising in the GI tract  (<a class="graphic graphic_table graphicRef110739" href="/d/graphic/110739.html" rel="external">table 1</a>); there are no AJCC prognostic stage groupings [<a href="#rid15">15</a>].</p><p>In general, outcomes for leiomyosarcomas at specific segments of the GI tract are less favorable than for GISTs arising in those segments. (See <a class="local">'Presentation and management at specific sites'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h1">PRESENTATION AND MANAGEMENT AT SPECIFIC SITES</span></p><p class="headingAnchor" id="H5"><span class="h2">Esophagus</span><span class="headingEndMark"> — </span>Mesenchymal tumors are most common in the mid to distal third of the esophagus. They are usually small and asymptomatic, but occasionally grow to enormous size and produce dysphagia.</p><p class="headingAnchor" id="H6"><span class="h3">Leiomyomas and leiomyosarcomas</span><span class="headingEndMark"> — </span>Although rare elsewhere in the gastrointestinal (GI) tract, the majority of mesenchymal tumors affecting the esophagus are leiomyomas [<a href="#rid16">16</a>]. Leiomyosarcomas are far less common [<a href="#rid16">16</a>].</p><p>Leiomyomas are more common in men, and often detected incidentally on a <a class="drug drug_general" data-topicid="9180" href="/d/drug information/9180.html" rel="external">barium</a> swallow or endoscopy performed for other reasons [<a href="#rid16">16,17</a>]. The tumors appear as rounded submucosal lesions with intact overlying mucosa and feel rubbery when gently palpated with the endoscope. Ulceration or bleeding is uncommon.</p><p>The histologic distinction between well-differentiated leiomyosarcoma and leiomyoma can be difficult. Endoscopic resection of all small submucosal tumors has been suggested to firmly establish their benignity. In one series of 62 patients with submucosal tumors of the esophagus, tumors less than 2 cm that were polypoid or had at least a round protrusion with moderate elevation were selected for endoscopic snare polypectomy [<a href="#rid17">17</a>]. Larger tumors, or those having only mild elevation, were treated by complete stripping of the overlying mucosa followed by enucleation using an electrocautery snare and a coagulation electrode. Tumors were completely resected in all but one patient, and there were no serious complications. Histologically, there were 56 leiomyomas, four granular cell tumors, one neurogenic tumor, and one cyst.</p><p>Despite these encouraging results, no malignant tumors were encountered in this series (with the exception of the granular cell tumors, which can be malignant), and the risk of complications is uncertain. The safety of this technique depends upon the endoscopist's experience.</p><p>A more conservative approach for small asymptomatic lesions that lack features suggesting malignancy is to perform follow-up examinations using endoscopic ultrasound (EUS). Follow-up studies consist of repeat EUS at six and 12 months. If no changes occur within one year, the follow-up intervals can be lengthened. Surgery should be performed if the tumor becomes symptomatic, enlarges to &gt;1 cm, or shows structural changes. Snare polypectomy should be reserved for lesions with mucosal elevations that meet the previously described criteria. Surgery is also indicated in any case in which a malignancy is suspected. (See  <a class="medical medical_review" href="/d/html/2530.html" rel="external">"Surgical management of resectable esophageal and esophagogastric junction cancers"</a>.)</p><p>Stable lesions that are &gt;2 cm or that produce dysphagia should be treated with appropriate surgical resection:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete resection of a small leiomyosarcoma can often be accomplished through local excision [<a href="#rid18">18</a>]. However, based upon the size of the tumor, resection may require a total or partial esophagectomy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Esophagectomy may also be needed for adequate treatment of giant esophageal leiomyomas [<a href="#rid19">19</a>].</p><p></p><p>Five-year survival rates of approximately 30 to 40 percent are reported in patients with resected leiomyosarcoma [<a href="#rid20">20</a>], although less favorable results are reported by others [<a href="#rid16">16</a>]. Individual survival is strongly influenced by tumor differentiation and size.</p><p class="headingAnchor" id="H7"><span class="h3">GIST</span><span class="headingEndMark"> — </span>Esophageal GISTs are rare; this site accounts for only 1 percent of all GISTs reported in the Surveillance, Epidemiology and End Results (SEER) registry [<a href="#rid21">21</a>]. Esophageal GISTs have a similar clinical, endoscopic and radiographic appearance as leiomyomas, although they tend to be more enhancing on contrast-enhanced CT, are fludeoxyglucose (FDG)-avid on FDG-PET scanning, and can be reliably identified preoperatively by EUS-guided FNA, especially if immunohistochemical staining for KIT can be performed [<a href="#rid22">22,23</a>]. All well-circumscribed submucosal esophageal lesions that are &gt;2 cm, enlarging, or FDG-avid should undergo preoperative EUS with FNA, as these are not typical features of a leiomyoma. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Diagnostic evaluation'</a>.)</p><p>Esophageal GISTs are more difficult to manage than are GISTs arising in serosa-lined intraabdominal organs because of the lack of tumor confinement by a serosal layer, and the relative contraindication to segmental resection given the blood supply of the esophagus. Although local resection of small tumors confined to the wall of the distal esophagus is reasonable if negative resection margins can be achieved [<a href="#rid22">22,24</a>], an open en bloc esophagectomy may be required for tumors ≥2 cm and for those involving the GE junction. (See  <a class="medical medical_review" href="/d/html/2530.html" rel="external">"Surgical management of resectable esophageal and esophagogastric junction cancers"</a>.)</p><p>Neoadjuvant therapy should be considered to downstage the potential scope of the operation, and the patient should be referred to a center with experience in the multimodality approaches to esophageal GISTs. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors"</a>.)</p><p>While successful enucleation has been reported in smaller esophageal GIST with apparently favorable outcomes [<a href="#rid25">25</a>], the oncologic appropriateness of this limited surgery has not been evaluated in a prospective multicenter trial and cannot be routinely recommended as the best approach. </p><p>The optimal management of esophageal GISTs &lt;2 cm in size is controversial. European Society for Medical Oncology (ESMO) guidelines recommend endoscopic ultrasound and follow-up, reserving excision only for those esophageal nodules that increase in size [<a href="#rid8">8</a>]. Canadian guidelines suggest that all GISTs, even those &lt;1 cm, be excised because of the risk of metastases [<a href="#rid9">9</a>]. An algorithmic approach to management of GISTs ≤2 cm based upon size and EUS appearance has been proposed  (<a class="graphic graphic_algorithm graphicRef139723" href="/d/graphic/139723.html" rel="external">algorithm 2</a>) [<a href="#rid11">11</a>]; however, this approach has not been prospectively validated. It has been adopted by the NCCN [<a href="#rid7">7</a>] for small gastric GISTs but not those at other sites. (See <a class="local">'Stomach'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Stomach</span><span class="headingEndMark"> — </span>The majority of soft tissue tumors arising in the stomach are GISTs, followed by leiomyomas; leiomyosarcomas are rare [<a href="#rid26">26</a>]. The stomach is the most frequent site for GISTs, which account for 1 to 3 percent of all stomach neoplasms  (<a class="graphic graphic_picture graphicRef52275" href="/d/graphic/52275.html" rel="external">picture 1</a>). GIST may arise anywhere in the stomach, but are most common in the fundus  (<a class="graphic graphic_figure graphicRef79793" href="/d/graphic/79793.html" rel="external">figure 1</a>). Further details on the clinical presentation of GISTs are discussed separately. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">GIST and leiomyoma</span><span class="headingEndMark"> — </span>On histopathology, leiomyomas are formed of fascicles of benign-appearing spindle cells without nuclear atypia, mitoses are sparse or absent, and necrosis virtually never occurs  (<a class="graphic graphic_picture graphicRef74175" href="/d/graphic/74175.html" rel="external">picture 2</a>). The nucleus is centrally located and oval, but it may be displaced to one side by distinct vacuoles, suggesting signet-ring cells. These vacuoles do not contain fat or mucosubstances, which differentiates them from liposarcomas and carcinomas. </p><p>The pathologic features of GISTs are discussed separately. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Histopathology'</a>.)</p><p>Both leiomyomas and gastric GISTs may be ≤0.5 cm or as large as 20 to 30 cm. Both tumors may grow both inwardly (intraluminal), outwardly (extraluminal), or a combination of both directions to form a dumbbell shape. Leiomyomas typically arise from the muscularis propria, are usually small and well-circumscribed and more likely to grow intraluminally (endogastric)  (<a class="graphic graphic_picture graphicRef58068" href="/d/graphic/58068.html" rel="external">picture 3</a>). By contrast, GISTs (and leiomyosarcomas) grow and expand in a predominantly extragastric fashion [<a href="#rid27">27</a>]. Multiple small leiomyomas (microleiomyomas) are found in 16 to 38 percent of resected stomachs.</p><p>Leiomyomas are typically asymptomatic, even when large in size. While most small GISTs are asymptomatic, large lesions ulcerate, and up to 60 percent present with bleeding [<a href="#rid28">28,29</a>]. Other symptoms include anorexia, weight loss, nausea, vomiting, and pain; gastric perforation is uncommon.</p><p>EUS-guided fine needle aspiration biopsy has emerged as an important method to secure the diagnosis of a gastric GIST. However, a preoperative diagnosis may not be possible if there is insufficient material to perform immunohistochemistry.</p><p>The treatment approach varies according to size. All nodules ≥2 cm should be excised. Submucosal lesions &lt;1 cm with EUS findings suggestive of benignity may be followed conservatively, using a similar protocol as for esophageal leiomyomas. (See <a class="local">'Leiomyomas and leiomyosarcomas'</a> above.)</p><p>The management of lesions between 1 and 2 cm is controversial, and guidelines from expert groups differ in their recommendations [<a href="#rid7">7-9</a>]. Some clinicians will resect tumors between 0.5 and 1.0 cm in size by endoscopic snare polypectomy, but there is a risk of perforation. If the decision is made to remove them, we prefer that these and other larger tumors be surgically resected (preferably by a laparoscopic approach, if feasible), because of the increased frequency of complications and the difficulty in excluding malignancy preoperatively. Even 1 cm GISTs are likely to have a KIT mutation, and the risk of growth and progression to malignancy is unknown [<a href="#rid30">30</a>] (see <a class="local">'General surgical principles'</a> above). Furthermore, these tumors are submucosal, so an endoscopic snare polypectomy may conceivably leave tumor tissue behind.</p><p>Whether all gastric GISTs &lt;2 cm need to be removed is controversial. The prognosis of gastric GISTs is better than those arising elsewhere in the intestinal tract [<a href="#rid31">31</a>]. (See <a class="local">'General surgical principles'</a> above.) </p><p>Larger tumor size and high mitotic rate correlate with a relative rather than absolute risk of malignant behavior  (<a class="graphic graphic_table graphicRef139776" href="/d/graphic/139776.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef60930" href="/d/graphic/60930.html" rel="external">table 3</a>). Nevertheless, even lesions &lt;2 cm in diameter with &lt;1 mitosis per 10 high-power fields (HPFs) occasionally metastasize to the liver, peritoneum, or lung [<a href="#rid28">28,29</a>]. Canadian guidelines suggest that even small GISTs &lt;1 cm should be excised because of the risk of metastases [<a href="#rid9">9</a>].</p><p>An algorithmic approach to management of gastric GIST based upon size and EUS appearance has been proposed  (<a class="graphic graphic_algorithm graphicRef139723" href="/d/graphic/139723.html" rel="external">algorithm 2</a>) [<a href="#rid11">11</a>]. Although not prospectively validated, this approach was adopted by the NCCN [<a href="#rid7">7</a>] for management of gastric GISTs (but not those at other GI sites). Complete surgical resection is recommended for small gastric GISTs &lt;2 cm at high risk of recurrence based upon EUS appearance (irregular borders, cystic spaces, ulceration, echogenic foci, or heterogeneity in appearance). </p><p>For tumors that lack these features, surveillance using endoscopic ultrasound is an option. EUS surveillance may be offered after a risk-benefit discussion with the patient. However, many clinicians limit endoscopic resection and/or surveillance to patients who are at higher risk for surgical complications. Data are limited for the optimal interval between surveillance studies. One approach is to have a short-term initial assessment (eg, within three to six months). If the tumor remains stable, then the follow-up interval can be lengthened. The tumor should be resected if it cannot be assessed endoscopically, becomes symptomatic (eg, dysphagia), increases in size, or shows structural changes or high-risk endoscopic features on EUS. Imaging surveillance is discussed separately. (See <a class="local">'Posttreatment follow-up'</a> below.)</p><p>Minimally invasive (laparoscopic or robotic) resection of gastric GISTs is safe and effective but should only be performed by surgeons with expertise in the laparoscopic or robotic management of upper GI cancers or sarcomas [<a href="#rid32">32-36</a>]. (See  <a class="medical medical_review" href="/d/html/15161.html" rel="external">"Partial gastrectomy and gastrointestinal reconstruction"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Leiomyosarcoma</span><span class="headingEndMark"> — </span>On histopathology, the cells of a true leiomyosarcoma are characteristically elongated with an abundance of cytoplasm. Multinucleated giant cells are common  (<a class="graphic graphic_picture graphicRef114812" href="/d/graphic/114812.html" rel="external">picture 4</a>). Most are histologically high grade, and by immunohistochemistry, they express smooth muscle actin, desmin, or both  (<a class="graphic graphic_table graphicRef79128" href="/d/graphic/79128.html" rel="external">table 4</a>) [<a href="#rid37">37</a>]. Epithelioid changes, in which the cells become rounded or polygonal cells with a clear perinuclear space lacking smooth muscle myofibrils, may occur in an otherwise typical leiomyosarcoma.</p><p>Gastric leiomyosarcomas are rare. Symptoms include nausea, vomiting, pain, weight loss, bleeding, or a palpable mass [<a href="#rid38">38,39</a>]. These tumors may be large at presentation (median 10 cm in one report of 15 cases [<a href="#rid38">38</a>]), and there may be local invasion of adjacent organs. Leiomyosarcomas have varying degrees of internal necrosis which produce an inhomogeneous pattern on EUS and heterogeneous contrast enhancement on CT. Dystrophic calcification may also be present [<a href="#rid39">39-41</a>]. Ninety percent of tumors are located in the fundus and body. Hematogenous dissemination may occur to liver and lungs [<a href="#rid39">39</a>].</p><p>Local resection with an adequate margin is the treatment of choice in the absence of invasion to adjacent structures [<a href="#rid38">38,40</a>]. En bloc resection is needed if adjacent organs are invaded. Nodal dissection is unnecessary since nodal metastases are rare [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/15161.html" rel="external">"Partial gastrectomy and gastrointestinal reconstruction"</a>.)</p><p>In general, outcomes are less favorable than for gastric GIST. In a report of 15 cases of gastric leiomyosarcoma treated between 1981 and 1998 (median tumor size 10 cm), the three- and five-year survival rates following resection were 53 and 22 percent, respectively [<a href="#rid38">38</a>]. Others report markedly better outcomes in patients with gastric "leiomyosarcoma" (five-year disease-specific survival 93 percent), but it is likely that many of the patients included in this series would likely be classified as GIST by modern methods [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Small intestine</span><span class="headingEndMark"> — </span>The small intestine is the second most frequent site for smooth muscle tumors. Tumors are most commonly found in the jejunum, followed by the ileum and then duodenum [<a href="#rid42">42-45</a>].</p><p>The most common type of intestinal sarcoma is a GIST, accounting for 83 to 86 percent of cases [<a href="#rid46">46,47</a>]. The majority of previously classified leiomyosarcomas in older studies are in fact GISTs [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/2517.html" rel="external">"Epidemiology, clinical features, and types of small bowel neoplasms", section on 'Sarcoma'</a>.)</p><p>Small intestinal mesenchymal tumors are often large at diagnosis, and they commonly present with ulceration and bleeding, which can be massive  (<a class="graphic graphic_diagnosticimage graphicRef53060" href="/d/graphic/53060.html" rel="external">image 1</a>). On CT, small bowel leiomyomas may appear as a smoothly contoured, hypodense lesion immediately adjacent to the gut lumen, and may have internal foci of hemorrhage or necrosis  (<a class="graphic graphic_diagnosticimage graphicRef53060" href="/d/graphic/53060.html" rel="external">image 1</a>). Diagnostic imaging findings for GISTs are discussed separately. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Imaging the primary tumor'</a>.)</p><p>Other common presenting symptoms of small bowel sarcomas include pain, weight loss, perforation, or a palpable mass [<a href="#rid19">19</a>]. Because they tend to enlarge extraluminally, obstruction is rare and typically a late presenting symptom. By contrast, small bowel leiomyomas may obstruct the bowel as these tumors typically grow into the lumen  (<a class="graphic graphic_picture graphicRef60327" href="/d/graphic/60327.html" rel="external">picture 5</a>).</p><p>Surgical treatment for a localized, potentially resectable GIST and a leiomyosarcoma of the small bowel is similar and consists of en bloc segmental resection with tumor-free margins. Peritumoral as opposed to segmental resection should be avoided, as it is associated with a high risk of local recurrence [<a href="#rid48">48</a>]. Unlike adenocarcinoma and carcinoid, sarcomas such as GIST infrequently metastasize to regional mesenteric lymph nodes (5 percent on one database series of 1848 small intestinal GISTs [<a href="#rid13">13</a>], and mesenteric lymphadenectomy is neither necessary nor beneficial. There is less experience with laparoscopic resection of small bowel GISTs than with gastric GISTs [<a href="#rid49">49,50</a>]. (See  <a class="medical medical_review" href="/d/html/86841.html" rel="external">"Bowel resection techniques"</a>.)</p><p>For duodenal GISTs, local resection is appropriate when feasible, and pancreaticoduodenectomy should be reserved for lesions that are not amenable to local resection (eg, involvement of the papilla of Vater) [<a href="#rid51">51-55</a>]. The use of neoadjuvant therapy in patients with a locally advanced duodenal GIST may potentially allow some patients who would otherwise require pancreaticoduodenectomy to undergo local resection instead, although the frequency with which this occurs is unclear [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Neoadjuvant therapy'</a>.)</p><p>The prognosis of small intestine GISTs depends upon the adequacy of resection, tumor size, mitotic activity, and, in some (but not all [<a href="#rid56">56</a>]) series, location within the small bowel  (<a class="graphic graphic_table graphicRef139776" href="/d/graphic/139776.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef60930" href="/d/graphic/60930.html" rel="external">table 3</a>) [<a href="#rid42">42,44,45,57</a>]. In one series of 70 patients, five-year disease-free and overall survival rates were 67 and 87 percent, respectively [<a href="#rid44">44</a>]. There were no recurrences or deaths in patients with tumor size less than 5 cm, and no deaths in patients with a tumor mitotic rate less than 5 per 50 HPFs.</p><p class="headingAnchor" id="H13"><span class="h2">Colon and rectum</span><span class="headingEndMark"> — </span>Smooth muscle tumors are uncommon overall in the colon and rectum, and especially rare in the appendix [<a href="#rid58">58</a>]. In the rectum, the great majority of smooth muscle tumors are GISTs [<a href="#rid59">59</a>], and they usually present as small, hard nodules &lt;1 cm in diameter found incidentally during a clinical examination. Large tumors can ulcerate and mimic a rectal adenocarcinoma, with rectal bleeding, constipation, and abdominal discomfort [<a href="#rid60">60</a>]. In the colon, GISTs are more common than leiomyosarcomas, and they are typically transmural, with frequent intramural and outward bulging components [<a href="#rid37">37</a>].</p><p>Lesions in which a malignancy cannot be excluded should be resected surgically, regardless of size. Although leiomyomas could theoretically be enucleated, a standard colectomy based on the blood supply to the bowel, as is done for adenocarcinomas, is technically easier, and the complication rate should be comparable. However, because lymphatic metastases are rare for GIST, resection of the adjacent mesentery (and the performance of a mesorectal resection for rectal GISTs) is not necessary [<a href="#rid61">61,62</a>]. On the other hand, locally advanced colorectal GISTs can be large, bulky tumors. Rectal GISTs are a particular challenge for the surgeon because of the confined pelvic space and often dense adherence to the pelvic floor [<a href="#rid62">62</a>]. As a consequence, rectal GIST may require extensive surgery to achieve a surgically complete resection. Such cases should be evaluated for neoadjuvant therapy to reduce tumor size [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/15261.html" rel="external">"Overview of colon resection"</a> and  <a class="medical medical_review" href="/d/html/17127.html" rel="external">"Radical resection of rectal cancer", section on 'Total mesorectal excision'</a> and  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Rectal GISTs'</a>.)</p><p>Outcomes with surgery alone are poor, and a tumor site in the colon or rectum is recognized to confer a worse prognosis than location in the stomach  (<a class="graphic graphic_table graphicRef139776" href="/d/graphic/139776.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef60930" href="/d/graphic/60930.html" rel="external">table 3</a>). Outcomes appear to be better in patients treated with perioperative <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> [<a href="#rid61">61,63-65</a>]. In particular, positive resection margins are an important risk factor for poor survival in patients with rectal GIST. Especially for patients with high-risk tumors (&gt;5 cm or mitotic rate &gt;5 per 50 HPF), preoperative imatinib may increase the chance of a margin-negative resection [<a href="#rid63">63,65</a>] and for less radical sphincter-sparing surgery [<a href="#rid65">65,66</a>], and might improve survival over resection alone [<a href="#rid65">65,67</a>]. We prefer initial imatinib for most patients with a rectal GIST, unless the tumor is small and sphincter-preserving surgery is possible upfront. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Rectal GISTs'</a>.) </p><p class="headingAnchor" id="H211167337"><span class="h1">LOCALLY ADVANCED OR BORDERLINE RESECTABLE GIST</span></p><p class="headingAnchor" id="H1359776494"><span class="h2">KIT or PDGFRA mutated GIST</span><span class="headingEndMark"> — </span>For most patients with a nonmetastatic locally advanced or borderline resectable GIST that are <em>KIT</em> or non-D842V <em>PDGFRA</em> mutated, we offer neoadjuvant therapy  (<a class="graphic graphic_algorithm graphicRef139727" href="/d/graphic/139727.html" rel="external">algorithm 1</a>) prior to surgery to facilitate resection and reduce surgical morbidity. Indications for neoadjuvant therapy for GIST are discussed separately. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Indications for neoadjuvant therapy'</a>.)</p><p>Neoadjuvant therapy may allow patients to switch from an open to a minimally invasive (ie, laparoscopic or robotic) surgical approach, avoid complex multivisceral resection, or preserve the affected organ, such as the esophagus, esophagogastric junction, duodenum, or distal rectum. Surgery may be offered to patients whose disease is stable or responding to tyrosine kinase inhibitor (TKI) therapy, followed by a period of postoperative systemic therapy. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Postoperative management'</a>.)</p><p>For patients with a <em>PDGFRA</em> D842V mutated tumor, we do not use neoadjuvant therapy and, instead, proceed directly to surgery. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Neoadjuvant therapy'</a>.)</p><p class="headingAnchor" id="H3691702466"><span class="h2">KIT/PDGFRA wild-type GIST</span><span class="headingEndMark"> — </span>Approximately 10 to 15 percent of GISTs do not have a detectable <em>KIT</em> or platelet-derived growth factor receptor A (<em>PDGFRA</em>) mutation. <em>KIT</em>/<em>PDGFRA</em> wild-type GISTs are often localized to the stomach and multicentric in origin. Further details on the clinical presentation of patients with <em>KIT/PDGFRA</em> wild-type GISTs are discussed separately. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'KIT/PDGFRA wild-type GISTs'</a>.) </p><p>In such patients, disease progression/recurrence is frequent, but the natural history is indolent [<a href="#rid68">68,69</a>]. Although repeated resection tends to be associated with progressively decreasing event-free survival, there are no approved drug therapies for this cohort of GIST patients. Therefore, surgery for subsequent recurrences is a reasonable option for symptomatic patients and those with progressive growth. As an example, in one report of 76 individuals with wild-type GIST who underwent initial resection, event-free survival (defined as freedom from disease progression or recurrence) rates were 73, 58, 24, and 16 percent at 1, 2, 5, and 10 years, respectively [<a href="#rid70">70</a>]. However, at a median follow-up of 4.1 years, only five patients died. </p><p class="headingAnchor" id="H15"><span class="h1">METASTATIC GIST WITH POTENTIALLY RESECTABLE DISEASE</span></p><p class="headingAnchor" id="H3035991826"><span class="h2">Neoadjuvant therapy followed by surgery</span><span class="headingEndMark"> — </span>For patients with potentially resectable metastatic GIST (including liver and peritoneal metastases), we suggest neoadjuvant systemic therapy rather than initial surgery. Surgery may be offered to patients who become resectable after neoadjuvant <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> and for those with primary imatinib resistance who become resectable after therapy with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>. For patients who develop extensive disease progression while on neoadjuvant therapy, we do not pursue further surgery.</p><p>Cytoreductive surgery in this setting often requires extensive, potentially morbid procedures, such as gastrectomy, hepatectomy, and pancreatic resection, and should be carried out in centers of excellence. </p><p>All patients should resume systemic therapy indefinitely after resection of metastatic disease. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"</a>.)</p><p>Although therapy with tyrosine kinase inhibitors (TKIs) has become the first-line treatment for metastatic GIST, there are several reasons integrate surgical resection into the treatment patients who are receiving these drugs for metastatic disease but have potentially resectable disease:</p><p class="bulletIndent1"><span class="glyph">●</span>While TKIs control tumor growth in over 80 percent of patients, complete responses are only rarely achieved [<a href="#rid71">71-73</a>]. Even tumor masses that appear nonviable by metabolic imaging (eg, with PET scans) usually contain viable cancer cells [<a href="#rid73">73,74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients who initially respond to <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> eventually acquire resistance via additional mutations in the KIT gene. The median time to progression is approximately two years. Response rates to second-line <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> and third-line <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> are low, and responses are less durable. The goal of metastasectomy is to remove disease before secondary resistance develops and stop disease progression by eliminating resistant clones.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The liver and peritoneum are the most common metastatic sites, and approximately 25 to 30 percent of patients who present with recurrent/metastatic disease have potentially resectable disease.</p><p></p><p>The critical question of whether surgery provides additional benefit over remaining on TKI therapy alone without surgery is unanswered. Two trials addressing this question were begun in <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00956072&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSy6SK%2BKLScyZWFvWcVyQ2oiUh5SKK600ybwpjIINDuzrw%3D%3D&amp;TOPIC_ID=7727" target="_blank">Europe</a> and in China, but both failed to recruit quickly enough to meet target accrual. In the absence of randomized trials, single-institution and multi-institutional retrospective studies document long-term disease control and longer overall survival (OS) for selected patients with limited metastatic disease who undergo metastasectomy [<a href="#rid75">75-87</a>].</p><p>In general, resection appears to benefit responding patients (ie, those who have a partial response, stable disease, or focal progression, and possibly those with isolated sites of progression) but has little to offer those who experience generalized or multifocal disease progression while receiving a TKI [<a href="#rid77">77,79,87</a>].</p><p>As an example, one review of the experience from two institutions included 400 consecutive operations on 323 patients with metastatic GIST who were receiving a TKI [<a href="#rid87">87</a>]. As expected, patients who underwent surgery while receiving <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> had a significantly longer progression-free survival (PFS) from the date of metastasectomy compared with those on <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> (16 versus 7 months). Among the patients receiving imatinib, radiographic response at the time of surgery was predictive of both PFS and OS after surgery:</p><p class="bulletIndent1"><span class="glyph">●</span>Responsive disease – Median PFS 36 months, median OS not reached</p><p class="bulletIndent1"><span class="glyph">●</span>Stable disease – Median PFS 30 months, OS 110 months</p><p class="bulletIndent1"><span class="glyph">●</span>Unifocal progressive disease – 11 months, OS 59 months</p><p class="bulletIndent1"><span class="glyph">●</span>Multifocal progressive disease – 6 months, OS 24 months</p><p></p><p>Radiographic response was not predictive of PFS or OS in patients on <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> prior to surgery. On multivariate analysis, a metastatic mitotic index &gt;5 per 50 high-power fields (HPFs), multifocal progressive disease, and a grossly incomplete (R2) resection were prognostic of worse PFS and OS after surgery.</p><p>Resection, even if complete, does not eliminate the need for continued treatment with TKI therapy. PFS is significantly shorter in patients who discontinue treatment as compared with those who continue the drug after resection [<a href="#rid77">77,79</a>].</p><p>Thus, surgery may be considered as the <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> response permits. If there are signs of isolated progression (ie, one or two lesions growing out of proportion to other sites of responding disease), resection of such lesions is a reasonable approach, although it is not clear if survival is prolonged compared with a change in systemic therapy. For patients with more generalized progression of disease, surgery is not helpful, and other systemic options should be pursued. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Treatment of disease refractory to imatinib'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Timing of surgery</span><span class="headingEndMark"> — </span>The appropriate timing of surgical intervention for patients with metastatic GIST is unknown. Some propose that patients be treated for six to nine months with neoadjuvant systemic therapy and subsequently evaluated for surgery if the disease appears completely grossly resectable [<a href="#rid79">79</a>]. While it has been shown that tumor load continues to decrease even after one year of <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, the median time to best response is 3.5 months, and there is little incremental tumor shrinkage after nine months [<a href="#rid88">88</a>].</p><p>All patients treated with presurgical <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> should resume TKI therapy postoperatively, typically with the same agent and dose. In theory, this maximizes the potential benefit derived from the TK inhibitor by extending the time each patient is on that drug prior to proceeding to the next line of therapy. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Treatment of disease refractory to imatinib'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Surgery for liver metastases</span><span class="headingEndMark"> — </span>The liver is the site of recurrence in as many as 67 percent of patients with relapsed GIST [<a href="#rid89">89</a>]. Prior to the <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> era, these patients were treated like other soft tissue sarcomas metastatic to the liver, with resection when technically feasible [<a href="#rid90">90,91</a>]. The available data on GIST liver metastases suggest five-year survival rates from 27 to 34 percent in patients undergoing resection alone [<a href="#rid92">92-94</a>].</p><p>For patients with isolated liver metastases, hepatic resection combined with <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> provides the greatest opportunity for long-term disease control [<a href="#rid93">93,95-97</a>].</p><p>A course of preoperative therapy (ie, three to nine months) is preferred in most cases, as it not only has the potential to reduce the extent of needed surgery, but it also permits the "biologic selection" of the best candidates for surgery, particularly if extensive procedures are planned. As an example, in the setting of multiple bilateral lesions (which are common with GIST), a two-staged approach may be needed, with or without portal vein embolization to increase the volume of the future liver remnant prior to hepatic resection [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/d/html/2488.html" rel="external">"Surgical resection of hepatocellular carcinoma", section on 'Portal vein embolization'</a>.)</p><p>An important component of periodic response assessment during neoadjuvant <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> is the understanding that a response to therapy consists less often of a change in tumor size or diameter, and more often of changes in density (ie, the development of cystic structures) and vascularity. This renders size-based tumor response criteria such as the Response Evaluation Criteria in Solid Tumors (RECIST)  (<a class="graphic graphic_table graphicRef74693" href="/d/graphic/74693.html" rel="external">table 5</a>) less useful. This subject is addressed in detail separately. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Assessing response to therapy'</a>.)</p><p>As with other sites of metastatic disease, resection following neoadjuvant <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> appears to benefit responding patients (ie, those who have a partial response, stable disease, or focal progression) but has little to offer those who experience generalized disease progression while receiving imatinib [<a href="#rid77">77</a>]. The optimal timing of attempted surgical resection (ie, at the time of maximal response to imatinib or at the first suggestion of local progression) is unclear, but the best response to imatinib is observed with three to nine months of therapy, with little change thereafter, suggesting this is a reasonable time to consider resection.</p><p>As with other sites of metastatic disease, hepatic resection, even if complete, does not eliminate the need for continued treatment with a TKI. PFS is significantly shorter in patients who discontinue <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> as compared with those who continue the drug after resection [<a href="#rid93">93</a>].</p><p>Existing clinical practice guidelines from the National Comprehensive Cancer Network (NCCN) [<a href="#rid7">7</a>] and European Society for Medical Oncology (ESMO) [<a href="#rid8">8</a>] recommend the indefinite administration of <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> for patients with resected metastases in the liver or peritoneum, even if the resection was complete. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Other local therapies for liver metastases</span><span class="headingEndMark"> — </span>There may be some therapeutic benefit for hepatic arterial embolization in patients with unresectable but isolated hepatic metastases, and from radiofrequency ablation (RFA) in patients with limited discordant progression of liver metastases during therapy with a TKI for advanced disease who are not candidates for hepatic resection. However, the place of embolization and RFA in the therapeutic armamentarium remains uncertain, particularly in view of the approval of <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> and <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>, multitargeted TKIs, for second- and third-line treatment, respectively, of imatinib-resistant disease.</p><p class="headingAnchor" id="H119647927"><span class="h3">Hepatic arterial embolization and chemoembolization</span><span class="headingEndMark"> — </span>For patients with isolated liver metastases, hepatic resection combined with <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> provides the greatest opportunity for long-term disease control, but many patients are ineligible because they have multifocal bilobar disease. Few data are available on the long-term benefit of hepatic artery embolization, chemoembolization, or radioembolization using yttrium-90 tagged microspheres for patients with isolated unresectable liver metastases [<a href="#rid98">98-102</a>]. The largest series consisted of 110 patients who underwent the chemoembolization (using <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> with or without an embolic agent) for liver metastases from GIST, 38 of whom had extrahepatic involvement [<a href="#rid98">98</a>]. Sixty-two were treated in the pre-imatinib era. The number of sessions per patient ranged from one to seven; 62 percent had two or more treatments. Most patients developed a temporary postembolization syndrome (abdominal pain, fever, nausea, vomiting), which was effectively managed with supportive care alone. Moderate to severe adverse events (death, respiratory distress, myelosuppression, cholecystitis, sepsis, pulmonary embolism, symptomatic pleural effusion, and hyponatremia-induced seizures) developed in 25 (12 percent).</p><p>Among the 85 patients who could be assessed, 12 had a partial radiologic response (14 percent, according to RECIST) and 74 percent had stable disease. The median liver PFS was 8.2 months, a value which is comparable to that reported in other smaller series (8 and 10 months, respectively) [<a href="#rid99">99,100</a>]. Median OS was 17.2 months, but the contribution of chemoembolization to this value could not be ascertained because of the use of other therapies, including <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, after disease progression. Concomitant imatinib prolonged survival time.</p><p>In a later analysis by this group of 14 patients who underwent hepatic artery embolization or chemoembolization for imatinib-refractory disease, the PFS in the liver were 31 percent at both one and three years, and the median PFS and OS times were 7 and 9.7 months, respectively [<a href="#rid101">101</a>].</p><p>These data suggest a possible therapeutic role for hepatic arterial embolization in patients with unresectable but isolated liver metastases from GISTs. However, the benefit of chemoembolization or radioembolization over bland embolization alone is unclear; there are no comparative trials. Furthermore, the place of any type of embolization in the therapeutic armamentarium remains uncertain, particularly in view of the approval of <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> and <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a>, as second- and third-line multitargeted TK inhibitors, for imatinib-resistant disease. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Sunitinib'</a>.)</p><p>Our general practice is to consider embolization if there is multifocal disease progression in liver despite use of available systemic therapeutic options, although each patient must be considered individually.</p><p class="headingAnchor" id="H119647951"><span class="h3">Radiofrequency ablation</span><span class="headingEndMark"> — </span>The use of thermal ablation to produce necrosis in focal hepatic malignancies has been established in patients who are not otherwise candidates for surgery. (See  <a class="medical medical_review" href="/d/html/2487.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"</a> and  <a class="medical medical_review" href="/d/html/2515.html" rel="external">"Nonsurgical local treatment strategies for colorectal cancer liver metastases"</a>.)</p><p>Few studies have explored the efficacy of RFA in patients with liver metastases from GIST [<a href="#rid91">91,93</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One report included nine patients with metastatic GIST who had RFA for a single or limited number of sites of progressive disease after a median 25 months of <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> (eight for liver metastases) [<a href="#rid91">91</a>]. In a preliminary report (median 4.2 months), all lesions were completely ablated, and four remained stable on continued imatinib. Longer-term follow-up of this cohort has not been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second series included 31 patients who underwent intraoperative RFA for sarcoma metastatic to liver (36 of the entire series of 66 patients had GIST) [<a href="#rid93">93</a>]. For 13 patients, RFA was the sole modality for tumors in unresectable locations, the remainder had resection of large lesions combined with RFA of smaller lesions deemed unresectable [<a href="#rid93">93</a>]. Patients who were treated with RFA alone or as a combined modality with resection had a significantly shorter disease-free interval than did those undergoing resection alone. The contribution of adjuvant <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> to RFA outcomes was not addressed.</p><p></p><p>These data suggest a possible therapeutic role for RFA in patients with advanced GIST who develop focal progression of liver metastases during <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> therapy and who are not otherwise candidates for surgery. Both lesion size and proximity to large blood vessels (which serve as a heat sink) impact on the feasibility of RFA as a therapeutic option.</p><p>However, as with hepatic arterial embolization, the place of RFA in the therapeutic armamentarium remains uncertain, particularly in view of the approval of <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, a multitargeted TK inhibitor, for imatinib-resistant disease. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Sunitinib'</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">POSTTREATMENT FOLLOW-UP</span><span class="headingEndMark"> — </span>Posttreatment follow-up is not required for a leiomyoma. For GIST and leiomyosarcoma, while there are no trials that have established the optimal duration, frequency, or components of follow-up, posttreatment surveillance is usually carried out for early detection of recurrent disease that may be amenable to additional treatment. For GIST and leiomyosarcoma, the recommendations differ slightly.</p><p class="headingAnchor" id="H6016720"><span class="h2">GIST</span><span class="headingEndMark"> — </span>The approach to follow-up after treatment of a GIST is discussed separately. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Posttreatment follow-up'</a>.)</p><p class="headingAnchor" id="H6016736"><span class="h2">Leiomyosarcoma</span><span class="headingEndMark"> — </span>Consensus-based guidelines for posttreatment follow-up for intraabdominal or retroperitoneal sarcomas are available from the NCCN [<a href="#rid7">7</a>] and include the following (see  <a class="medical medical_review" href="/d/html/115829.html" rel="external">"Management of locally recurrent retroperitoneal sarcoma", section on 'Posttreatment follow-up'</a> and  <a class="medical medical_review" href="/d/html/142600.html" rel="external">"Initial management of retroperitoneal soft tissue sarcoma", section on 'Posttreatment follow-up'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For completely resected tumors: physical examination with abdominal/pelvic imaging every three to six months for two to three years, and then annually; "consider" chest imaging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For sarcomas resected with positive margins: physical examination with abdominal/pelvic imaging every three to six months for two to three years, then every six months for the next two years, and then annually; "consider" chest imaging.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In either case, no specific recommendation is made for periodic chest imaging. However, given the higher rate of lung metastases with retroperitoneal and visceral leiomyosarcomas (as compared with other histologies), we recommend imaging of the chest in addition to the abdomen and pelvis on a regular schedule in these cases. Some clinicians routinely perform surveillance chest imaging for all patients with large, high-grade tumors, regardless of histology.</p><p></p><p>We agree with these guidelines.</p><p class="headingAnchor" id="H1946418107"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120170.html" rel="external">"Society guideline links: Gastrointestinal stromal tumors"</a>.)</p><p class="headingAnchor" id="H6653407"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/17046.html" rel="external">"Patient education: Soft tissue sarcoma (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of gastrointestinal mesenchymal neoplasms</strong> – Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal neoplasm affecting the gastrointestinal (GI) tract. The clinical presentation of GIST is discussed separately. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GISTs differ clinically and pathogenetically from true leiomyosarcomas (which are very rare in the GI tract and are predominantly found in the stomach) and leiomyomas (which occur predominantly in the esophagus, colon, and rectum). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The majority of mesenchymal tumors of the stomach are GISTs, while the majority of smooth muscle tumors in the esophagus are leiomyomas. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular alterations in GIST</strong> – Molecular alterations that are commonly identified in GISTs include mutations in <em>KIT</em>, platelet-derived growth factor receptor alpha (<em>PDGFRA</em>), and the family of succinate dehydrogenase (<em>SDH</em>) genes. (See  <a class="medical medical_review" href="/d/html/7745.html" rel="external">"Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors", section on 'Molecular alterations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment for GIST</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Resectable GIST</strong> – We recommend resection for all localized GISTs ≥2 cm in size  (<a class="graphic graphic_algorithm graphicRef139723" href="/d/graphic/139723.html" rel="external">algorithm 2</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). There is no consensus on the management of incidentally encountered smaller GISTs, and their management must be individualized. Guidelines for treatment of intraabdominal sarcomas from the National Comprehensive Cancer Network (NCCN) [<a href="#rid7">7</a>] do not differentiate between tumors that are ≥2 cm and smaller ones. (See <a class="local">'General surgical principles'</a> above.)</p><p></p><p class="bulletIndent2">For potentially resectable gastric and intestinal GISTs, segmental (rather than peritumoral) visceral resection is preferred; regional lymphadenectomy is unnecessary. (See <a class="local">'Presentation and management at specific sites'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Locally advanced or borderline resectable GIST</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong><em>KIT</em></strong><strong> or non-D842V </strong><strong><em>PDGFRA</em></strong><strong> mutated GIST</strong> - For most patients with a nonmetastatic locally advanced or borderline resectable GIST that are <em>KIT</em> or non-D842V <em>PDGFRA</em> mutated, we offer neoadjuvant therapy  (<a class="graphic graphic_algorithm graphicRef139727" href="/d/graphic/139727.html" rel="external">algorithm 1</a>) prior to surgery to facilitate resection and reduce surgical morbidity. (See <a class="local">'KIT or PDGFRA mutated GIST'</a> above and  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Neoadjuvant therapy'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Other GIST tumors</strong> – For patients with a <em>PDGFRA</em> D842V mutation or those with wildtype tumors (neither <em>KIT</em> nor <em>PDGFRA</em> mutations), we do not use neoadjuvant therapy and, instead, proceed directly to surgery. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Neoadjuvant therapy'</a> and <a class="local">'KIT/PDGFRA wild-type GIST'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metastatic GIST, potentially resectable</strong> – For patients with potentially resectable metastatic GIST (including liver and peritoneal metastases), we suggest neoadjuvant systemic therapy rather than initial surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Surgery may be offered to patients who become resectable after neoadjuvant <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> and for those with primary imatinib resistance who become resectable after therapy with <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>. For patients who develop extensive disease progression while on neoadjuvant therapy, we do not pursue further surgery. (See <a class="local">'Metastatic GIST with potentially resectable disease'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cytoreductive surgery in this setting often requires extensive, potentially morbid procedures, such as gastrectomy, hepatectomy, and pancreatic resection, and should be carried out in centers of excellence. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>All patients should resume tyrosine kinase inhibitors (TKI) therapy indefinitely after resection of metastatic disease. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with isolated liver metastases</strong> – There may be some therapeutic benefit from hepatic arterial embolization in patients with unresectable but isolated liver metastases from GISTs, and from radiofrequency ablation (RFA) in patients with limited discordant progression of liver metastases during TKI therapy who are not candidates for surgical resection. However, the place of embolization and RFA in the therapeutic armamentarium remains uncertain, particularly in view of the targeted therapies available, for imatinib-resistant disease. (See  <a class="medical medical_review" href="/d/html/7725.html" rel="external">"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors", section on 'Treatment of disease refractory to imatinib'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttreatment surveillance of GIST</strong> – The posttreatment surveillance of GIST is discussed separately. (See  <a class="medical medical_review" href="/d/html/7730.html" rel="external">"Adjuvant and neoadjuvant therapy for gastrointestinal stromal tumors", section on 'Posttreatment follow-up'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leiomyosarcoma </strong>– Leiomyosarcomas are very rare in the GI tract and are predominantly found in the stomach. We recommend local resection with an adequate margin in the absence of invasion to adjacent structures (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). En bloc resection is needed if adjacent organs are invaded. As with GISTs, nodal dissection is not necessary because of the rarity of nodal metastases. (See <a class="local">'Stomach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttreatment surveillance of leiomyosarcoma</strong> – Following treatment, we suggest the following surveillance strategy (see <a class="local">'Leiomyosarcoma'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For completely resected tumors, physical examination with abdominal/pelvic imaging every three to six months for two to three years, then annually.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For sarcomas resected with positive margins, physical examination with abdominal/pelvic imaging every three to six months for two to three years, then every six months for the next two years, and then annually.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Given the higher rate of lung metastases with retroperitoneal and visceral leiomyosarcomas (as compared with other histologies), we recommend imaging of the chest, in addition to the abdomen and pelvis, on a regular schedule in these cases. Some clinicians also routinely perform surveillance chest imaging for all patients with large, high-grade tumors, regardless of histology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leiomyoma</strong> – Leiomyomas are benign smooth muscle tumors that occur predominantly in the esophagus, colon, and rectum. (See <a class="local">'Leiomyomas and leiomyosarcomas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All well-circumscribed submucosal esophageal lesions that are &gt;2 cm, enlarging, or fludeoxyglucose (FDG) avid should undergo preoperative endoscopic ultrasound (EUS) with fine needle aspiration (FNA), as these are not typical features of a leiomyoma.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgical removal is indicated if the tumor becomes symptomatic, enlarges to &gt;1 cm or shows structural changes during surveillance, or malignancy is suspected.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Posttreatment follow-up is not required for leiomyomas. </p><p></p><p class="headingAnchor" id="H2195725370"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges George Demetri, MD, and Jeffrey Morgan, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23:1109.</a></li><li><a class="nounderline abstract_t">Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1.</a></li><li><a class="nounderline abstract_t">Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999; 30:1213.</a></li><li><a class="nounderline abstract_t">Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13:577.</a></li><li><a class="nounderline abstract_t">Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28:889.</a></li><li class="breakAll">Atlas of Tumor Pathology: Tumors of the esophagus and stomach. Electronic fascicle v2.0b, Armed Forces Institute of Pathology, Washington DC.</li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4:64.</a></li><li><a class="nounderline abstract_t">Blackstein ME, Blay JY, Corless C, et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol 2006; 20:157.</a></li><li><a class="nounderline abstract_t">Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 Suppl 2:S1.</a></li><li><a class="nounderline abstract_t">Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol 2009; 6:363.</a></li><li><a class="nounderline abstract_t">Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004; 30:1098.</a></li><li><a class="nounderline abstract_t">Giuliano K, Nagarajan N, Canner J, et al. Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ? J Surg Oncol 2017; 115:351.</a></li><li><a class="nounderline abstract_t">Everett M, Gutman H. Surgical management of gastrointestinal stromal tumors: analysis of outcome with respect to surgical margins and technique. J Surg Oncol 2008; 98:588.</a></li><li class="breakAll">Raut CP, Maki RG, Baldini EH, et al. Soft tissue sarcoma of the abdomen and thoracic visceral organs. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.517.</li><li><a class="nounderline abstract_t">Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000; 24:211.</a></li><li><a class="nounderline abstract_t">Hyun JH, Jeen YT, Chun HJ, et al. Endoscopic resection of submucosal tumor of the esophagus: results in 62 patients. Endoscopy 1997; 29:165.</a></li><li><a class="nounderline abstract_t">Rocco G, Trastek VF, Deschamps C, et al. Leiomyosarcoma of the esophagus: results of surgical treatment. Ann Thorac Surg 1998; 66:894.</a></li><li><a class="nounderline abstract_t">Rijcken E, Kersting CM, Senninger N, Bruewer M. Esophageal resection for giant leiomyoma: report of two cases and a review of the literature. Langenbecks Arch Surg 2009; 394:623.</a></li><li><a class="nounderline abstract_t">Pesarini AC, Ernst H, Ell C, et al. [Leiomyosarcoma of the esophagus. Clinical aspects, diagnosis and therapy based on an individual case]. Med Klin (Munich) 1997; 92:234.</a></li><li><a class="nounderline abstract_t">Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005; 100:162.</a></li><li><a class="nounderline abstract_t">Blum MG, Bilimoria KY, Wayne JD, et al. Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors. Ann Thorac Surg 2007; 84:1717.</a></li><li><a class="nounderline abstract_t">Winant AJ, Gollub MJ, Shia J, et al. Imaging and clinicopathologic features of esophageal gastrointestinal stromal tumors. AJR Am J Roentgenol 2014; 203:306.</a></li><li><a class="nounderline abstract_t">Lee HJ, Park SI, Kim DK, Kim YH. Surgical resection of esophageal gastrointestinal stromal tumors. Ann Thorac Surg 2009; 87:1569.</a></li><li><a class="nounderline abstract_t">Robb WB, Bruyere E, Amielh D, et al. Esophageal gastrointestinal stromal tumor: is tumoral enucleation a viable therapeutic option? Ann Surg 2015; 261:117.</a></li><li><a class="nounderline abstract_t">Agaimy A, Wünsch PH. True smooth muscle neoplasms of the gastrointestinal tract: morphological spectrum and classification in a series of 85 cases from a single institute. Langenbecks Arch Surg 2007; 392:75.</a></li><li><a class="nounderline abstract_t">Davis GB, Blanchard DK, Hatch GF 3rd, et al. Tumors of the stomach. World J Surg 2000; 24:412.</a></li><li><a class="nounderline abstract_t">Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52.</a></li><li><a class="nounderline abstract_t">Igwilo OC, Byrne MP, Nguyen KD, Atkinson J. Malignant gastric stromal tumor: unusual metastatic patterns. South Med J 2003; 96:512.</a></li><li><a class="nounderline abstract_t">Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160:1567.</a></li><li><a class="nounderline abstract_t">Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23:70.</a></li><li><a class="nounderline abstract_t">Bischof DA, Kim Y, Dodson R, et al. Open versus minimally invasive resection of gastric GIST: a multi-institutional analysis of short- and long-term outcomes. Ann Surg Oncol 2014; 21:2941.</a></li><li><a class="nounderline abstract_t">Koh YX, Chok AY, Zheng HL, et al. A systematic review and meta-analysis comparing laparoscopic versus open gastric resections for gastrointestinal stromal tumors of the stomach. Ann Surg Oncol 2013; 20:3549.</a></li><li><a class="nounderline abstract_t">Pelletier JS, Gill RS, Gazala S, Karmali S. A Systematic Review and Meta-Analysis of Open vs. Laparoscopic Resection of Gastric Gastrointestinal Stromal Tumors. J Clin Med Res 2015; 7:289.</a></li><li><a class="nounderline abstract_t">Li GZ, Fairweather M, Raut CP, Wang J. Use of Neoadjuvant Imatinib to Facilitate Minimally Invasive Resection of Gastric Gastrointestinal Stromal Tumors. Ann Surg Oncol 2022; 29:7104.</a></li><li><a class="nounderline abstract_t">Lwin TM, Fong ZV, Narayan RR, et al. Robotic Function-Preserving Resection of Gastric Gastrointestinal Stromal Tumor. J Surg Res 2023; 290:164.</a></li><li><a class="nounderline abstract_t">Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24:1339.</a></li><li><a class="nounderline abstract_t">Hsieh CC, Shih CS, Wu YC, et al. Leiomyosarcoma of the gastric cardia and fundus. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62:418.</a></li><li><a class="nounderline abstract_t">Pannu HK, Hruban RH, Fishman EK. CT of gastric leiomyosarcoma: patterns of involvement. AJR Am J Roentgenol 1999; 173:369.</a></li><li><a class="nounderline abstract_t">Katai H, Sasako M, Sano T, Maruyama K. Surgical treatment for gastric leiomyosarcoma. Ann Chir Gynaecol 1998; 87:293.</a></li><li><a class="nounderline abstract_t">Lee SH, Ha HK, Byun JY, et al. Radiological features of leiomyomatous tumors of the colon and rectum. J Comput Assist Tomogr 2000; 24:407.</a></li><li><a class="nounderline abstract_t">Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30:477.</a></li><li><a class="nounderline abstract_t">Blanchard DK, Budde JM, Hatch GF 3rd, et al. Tumors of the small intestine. World J Surg 2000; 24:421.</a></li><li><a class="nounderline abstract_t">Huang CC, Yang CY, Lai IR, et al. Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. World J Surg 2009; 33:828.</a></li><li><a class="nounderline abstract_t">Yang WL, Yu JR, Wu YJ, et al. Duodenal gastrointestinal stromal tumor: clinical, pathologic, immunohistochemical characteristics, and surgical prognosis. J Surg Oncol 2009; 100:606.</a></li><li><a class="nounderline abstract_t">Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249:63.</a></li><li><a class="nounderline abstract_t">Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003; 27:625.</a></li><li><a class="nounderline abstract_t">Lee SY, Goh BK, Sadot E, et al. Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Ann Surg Oncol 2017; 24:202.</a></li><li><a class="nounderline abstract_t">Nguyen SQ, Divino CM, Wang JL, Dikman SH. Laparoscopic management of gastrointestinal stromal tumors. Surg Endosc 2006; 20:713.</a></li><li><a class="nounderline abstract_t">Oida Y, Motojuku M, Morikawa G, et al. Laparoscopic-assisted resection of gastrointestinal stromal tumor in small intestine. Hepatogastroenterology 2008; 55:146.</a></li><li><a class="nounderline abstract_t">Tien YW, Lee CY, Huang CC, et al. Surgery for gastrointestinal stromal tumors of the duodenum. Ann Surg Oncol 2010; 17:109.</a></li><li><a class="nounderline abstract_t">Johnston FM, Kneuertz PJ, Cameron JL, et al. Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis. Ann Surg Oncol 2012; 19:3351.</a></li><li><a class="nounderline abstract_t">Colombo C, Ronellenfitsch U, Yuxin Z, et al. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. Ann Surg Oncol 2012; 19:3361.</a></li><li><a class="nounderline abstract_t">Chok AY, Koh YX, Ow MY, et al. A systematic review and meta-analysis comparing pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors. Ann Surg Oncol 2014; 21:3429.</a></li><li><a class="nounderline abstract_t">Duffaud F, Meeus P, Bachet JB, et al. Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG). Eur J Surg Oncol 2014; 40:1369.</a></li><li><a class="nounderline abstract_t">Zhang Q, Shou CH, Yu JR, et al. Prognostic characteristics of duodenal gastrointestinal stromal tumours. Br J Surg 2015; 102:959.</a></li><li><a class="nounderline abstract_t">Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8:50.</a></li><li><a class="nounderline abstract_t">Miettinen M, Sobin LH. Gastrointestinal stromal tumors in the appendix: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol 2001; 25:1433.</a></li><li><a class="nounderline abstract_t">Miettinen M, Furlong M, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25:1121.</a></li><li><a class="nounderline abstract_t">Manouras A, Pappas A, Katergiannakis V, et al. Gastrointestinal stromal tumors of the rectum: report of five cases. Acta Gastroenterol Belg 2009; 72:257.</a></li><li><a class="nounderline abstract_t">Tielen R, Verhoef C, van Coevorden F, et al. Surgical management of rectal gastrointestinal stromal tumors. J Surg Oncol 2013; 107:320.</a></li><li><a class="nounderline abstract_t">Birkenmaier A, Ries JJ, Kuhle J, et al. Placental α-microglobulin-1 to detect uncertain rupture of membranes in a European cohort of pregnancies. Arch Gynecol Obstet 2012; 285:21.</a></li><li><a class="nounderline abstract_t">Liu H, Yan Z, Liao G, Yin H. Treatment strategy of rectal gastrointestinal stromal tumor (GIST). J Surg Oncol 2014; 109:708.</a></li><li><a class="nounderline abstract_t">Jakob J, Mussi C, Ronellenfitsch U, et al. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Ann Surg Oncol 2013; 20:586.</a></li><li><a class="nounderline abstract_t">Cavnar MJ, Wang L, Balachandran VP, et al. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome. Ann Surg Oncol 2017; 24:3972.</a></li><li><a class="nounderline abstract_t">Wilkinson MJ, Fitzgerald JE, Strauss DC, et al. Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib. Br J Surg 2015; 102:965.</a></li><li><a class="nounderline abstract_t">Hawkins AT, Wells KO, Krishnamurty DM, et al. Preoperative Chemotherapy and Survival for Large Anorectal Gastrointestinal Stromal Tumors: A National Analysis of 333 Cases. Ann Surg Oncol 2017; 24:1195.</a></li><li><a class="nounderline abstract_t">Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol 2005; 29:1373.</a></li><li><a class="nounderline abstract_t">Pappo AS, Janeway KA. Pediatric gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009; 23:15.</a></li><li><a class="nounderline abstract_t">Weldon CB, Madenci AL, Boikos SA, et al. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol 2017; 35:523.</a></li><li><a class="nounderline abstract_t">Carboni F, Carlini M, Scardamaglia F, et al. Gastrointestinal stromal tumors of the stomach. A ten-year surgical experience. J Exp Clin Cancer Res 2003; 22:379.</a></li><li><a class="nounderline abstract_t">Chacón M, Roca E, Huertas E, et al. CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol 2005; 23:1580.</a></li><li><a class="nounderline abstract_t">Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005; 117:316.</a></li><li><a class="nounderline abstract_t">Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11:4182.</a></li><li><a class="nounderline abstract_t">Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14:14.</a></li><li><a class="nounderline abstract_t">Bonvalot S, Eldweny H, Péchoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006; 13:1596.</a></li><li><a class="nounderline abstract_t">Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24:2325.</a></li><li><a class="nounderline abstract_t">Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007; 245:341.</a></li><li><a class="nounderline abstract_t">DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007; 245:347.</a></li><li><a class="nounderline abstract_t">Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006; 93:304.</a></li><li><a class="nounderline abstract_t">Al-Batran SE, Hartmann JT, Heidel F, et al. Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer 2007; 10:145.</a></li><li><a class="nounderline abstract_t">Yeh CN, Chen TW, Tseng JH, et al. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol 2010; 102:599.</a></li><li><a class="nounderline abstract_t">Mussi C, Ronellenfitsch U, Jakob J, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol 2010; 21:403.</a></li><li><a class="nounderline abstract_t">Bauer S, Rutkowski P, Hohenberger P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol 2014; 40:412.</a></li><li><a class="nounderline abstract_t">Park SJ, Ryu MH, Ryoo BY, et al. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses. Ann Surg Oncol 2014; 21:4211.</a></li><li><a class="nounderline abstract_t">Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, et al. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol 2015; 22:2948.</a></li><li><a class="nounderline abstract_t">Fairweather M, Balachandran VP, Li GZ, et al. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis. Ann Surg 2018; 268:296.</a></li><li><a class="nounderline abstract_t">Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127.</a></li><li><a class="nounderline abstract_t">DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51.</a></li><li><a class="nounderline abstract_t">Zalinski S, Palavecino M, Abdalla EK. Hepatic resection for gastrointestinal stromal tumor liver metastases. Hematol Oncol Clin North Am 2009; 23:115.</a></li><li><a class="nounderline abstract_t">Dileo P, Randhawa R, Vansonnenberg E, et al. Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM) (abstract). J Clin Oncol 2004; 22:9024.</a></li><li><a class="nounderline abstract_t">DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg 2001; 234:540.</a></li><li><a class="nounderline abstract_t">Pawlik TM, Vauthey JN, Abdalla EK, et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006; 141:537.</a></li><li><a class="nounderline abstract_t">Nunobe S, Sano T, Shimada K, et al. Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas. Jpn J Clin Oncol 2005; 35:338.</a></li><li><a class="nounderline abstract_t">Rutkowski P, Nyckowski P, Grzesiakowska U, et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). Neoplasma 2003; 50:438.</a></li><li><a class="nounderline abstract_t">Xia L, Zhang MM, Ji L, et al. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today 2010; 40:936.</a></li><li><a class="nounderline abstract_t">Turley RS, Peng PD, Reddy SK, et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer 2012; 118:3571.</a></li><li><a class="nounderline abstract_t">Kobayashi K, Gupta S, Trent JC, et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer 2006; 107:2833.</a></li><li><a class="nounderline abstract_t">Mavligit GM, Zukwiski AA, Ellis LM, et al. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer 1995; 75:2083.</a></li><li><a class="nounderline abstract_t">Rajan DK, Soulen MC, Clark TW, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001; 12:187.</a></li><li><a class="nounderline abstract_t">Kobayashi K, Szklaruk J, Trent JC, et al. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors. Am J Clin Oncol 2009; 32:574.</a></li><li><a class="nounderline abstract_t">Rathmann N, Diehl SJ, Dinter D, et al. Radioembolization in patients with progressive gastrointestinal stromal tumor liver metastases undergoing treatment with tyrosine kinase inhibitors. J Vasc Interv Radiol 2015; 26:231.</a></li></ol></div><div id="topicVersionRevision">Topic 7727 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10478672" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213830" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534170" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gastrointestinal stromal tumors: recent advances in understanding of their biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10824931" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223958" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223958" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15223958" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19454466" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16550259" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17624289" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365407" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A guide for the diagnosis and management of gastrointestinal stromal cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15522557" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27885685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19072850" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Surgical management of gastrointestinal stromal tumors: analysis of outcome with respect to surgical margins and technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19072850" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Surgical management of gastrointestinal stromal tumors: analysis of outcome with respect to surgical margins and technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10680889" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9201464" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Endoscopic resection of submucosal tumor of the esophagus: results in 62 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768947" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Leiomyosarcoma of the esophagus: results of surgical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594855" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Esophageal resection for giant leiomyoma: report of two cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9221308" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : [Leiomyosarcoma of the esophagus. Clinical aspects, diagnosis and therapy based on an individual case].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654796" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954092" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25055264" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Imaging and clinicopathologic features of esophageal gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19379907" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Surgical resection of esophageal gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25062398" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Esophageal gastrointestinal stromal tumor: is tumoral enucleation a viable therapeutic option?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17021790" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : True smooth muscle neoplasms of the gastrointestinal tract: morphological spectrum and classification in a series of 85 cases from a single institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706913" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tumors of the stomach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613856" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12911195" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Malignant gastric stromal tumor: unusual metastatic patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12000708" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17193820" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Gastrointestinal stromal tumors: pathology and prognosis at different sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24763984" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Open versus minimally invasive resection of gastric GIST: a multi-institutional analysis of short- and long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23793362" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A systematic review and meta-analysis comparing laparoscopic versus open gastric resections for gastrointestinal stromal tumors of the stomach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25780475" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A Systematic Review and Meta-Analysis of Open vs. Laparoscopic Resection of Gastric Gastrointestinal Stromal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35624191" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Use of Neoadjuvant Imatinib to Facilitate Minimally Invasive Resection of Gastric Gastrointestinal Stromal Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37269799" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Robotic Function-Preserving Resection of Gastric Gastrointestinal Stromal Tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11023095" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10418174" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Leiomyosarcoma of the gastric cardia and fundus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430139" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : CT of gastric leiomyosarcoma: patterns of involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9891769" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Surgical treatment for gastric leiomyosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10864076" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Radiological features of leiomyomatous tumors of the colon and rectum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625094" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706914" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tumors of the small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19198935" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19697360" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Duodenal gastrointestinal stromal tumor: clinical, pathologic, immunohistochemical characteristics, and surgical prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19106677" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12717247" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27624583" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16502196" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Laparoscopic management of gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18507095" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Laparoscopic-assisted resection of gastrointestinal stromal tumor in small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841981" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Surgery for gastrointestinal stromal tumors of the duodenum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22878613" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22843188" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24854490" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A systematic review and meta-analysis comparing pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24994075" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25980461" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prognostic characteristics of duodenal gastrointestinal stromal tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11206225" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11684962" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Gastrointestinal stromal tumors in the appendix: a clinicopathologic and immunohistochemical study of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11688571" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19637785" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Gastrointestinal stromal tumors of the rectum: report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22806955" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Surgical management of rectal gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21475966" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Placentalα-microglobulin-1 to detect uncertain rupture of membranes in a European cohort of pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24510506" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment strategy of rectal gastrointestinal stromal tumor (GIST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22965573" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29058144" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25970743" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28050726" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Preoperative Chemotherapy and Survival for Large Anorectal Gastrointestinal Stromal Tumors: A National Analysis of 333 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16160481" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19248968" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pediatric gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28029307" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14582694" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Gastrointestinal stromal tumors of the stomach. A ten-year surgical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15735135" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15900603" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15930355" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17072676" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16957966" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16710031" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17435538" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17435539" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16496358" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17922091" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20976730" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628568" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24491288" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24980089" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25608769" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448384" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451219" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636102" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19248975" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hepatic resection for gastrointestinal stromal tumor liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM) (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11573047" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Results of hepatic resection for sarcoma metastatic to liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16785353" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928191" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Surgery including liver resection for metastatic gastrointestinal stromal tumors or gastrointestinal leiomyosarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14689066" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20872196" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22086856" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17096432" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7697597" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11265882" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636238" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25434477" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Radioembolization in patients with progressive gastrointestinal stromal tumor liver metastases undergoing treatment with tyrosine kinase inhibitors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
